616 related articles for article (PubMed ID: 35507087)
1. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
2. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
3. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
4. [Biomarkers in cardio-oncology patients].
Totzeck M; Glas M; Rassaf T
Internist (Berl); 2020 Nov; 61(11):1114-1119. PubMed ID: 33025124
[TBL] [Abstract][Full Text] [Related]
5. Cardio-toxicity among patients with sarcoma: a cardio-oncology registry.
Shamai S; Rozenbaum Z; Merimsky O; Derakhshesh M; Moshkovits Y; Arnold J; Topilsky Y; Arbel Y; Laufer-Perl M
BMC Cancer; 2020 Jun; 20(1):609. PubMed ID: 32605637
[TBL] [Abstract][Full Text] [Related]
6. Troponins and Natriuretic Peptides in Cardio-Oncology Patients-Data From the ECoR Registry.
Hinrichs L; Mrotzek SM; Mincu RI; Pohl J; Röll A; Michel L; Mahabadi AA; Al-Rashid F; Totzeck M; Rassaf T
Front Pharmacol; 2020; 11():740. PubMed ID: 32508657
[TBL] [Abstract][Full Text] [Related]
7. Using cardiac biomarkers and treating cardiotoxicity in cancer.
Colombo A; Cardinale D
Future Cardiol; 2013 Jan; 9(1):105-18. PubMed ID: 23259478
[TBL] [Abstract][Full Text] [Related]
8. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
9. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
10. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
12. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
[TBL] [Abstract][Full Text] [Related]
13. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
14. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques.
Di Lisi D; Manno G; Novo G
Curr Probl Cardiol; 2021 Jun; 46(6):100818. PubMed ID: 33756178
[TBL] [Abstract][Full Text] [Related]
15. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
[TBL] [Abstract][Full Text] [Related]
19. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
20. Identifying cancer patients at risk for cardiotoxicity.
Salvatici M; Sandri MT
Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
